Windlas Biotech concludes EU GMP Inspection, receives 0 critical observations

Windlas Biotech Limited, one of the leading domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India, has concluded its European Union GMP Inspection carried out by National Institute of Pharmacy and Nutrition, Hungary for the Plant-IV situated at Dehradun with zero critical observations. The company had undergone this inspection from 11th to 13th April 2022.

Commenting on this Mr. Hitesh Windlass, Managing Director – Windlas Biotech said, "Based on our preliminary discussion with the agency in the sum-up meeting, we estimate zero critical observations and deficiencies, including no observations related to Data Integrity issue. Inspection report will be issued by the agency within 30 days of completion of inspection. The successful completion of this inspection will enable the company to explore new geographical expansion avenues and reinforce the presence in entire European Market."

Shares of Windlas Biotech Ltd was last trading in BSE at Rs. 236.25 as compared to the previous close of Rs. 236.80. The total number of shares traded during the day was 2100 in over 251 trades.

The stock hit an intraday high of Rs. 239.60 and intraday low of 235.25. The net turnover during the day was Rs. 497443.00.

Source : Equity Bulls

Keywords

WindlasBiotech EUGMP Inspection Dehradun